TRANSCURE-BIOSERVICES
3.6.2019 14:57:05 CEST | Business Wire | Press release
TransCure bioServices (France), a one-stop-shop preclinical services company dedicated to in-vivo full human immune system mouse models, today announced that it has completed a 2.5 million euros funding with Financière Arbevel (France). This financing round will enable the company, healthy and profitable for the last three years, to accelerate its international sales growth as well as to expand in vivo preclinical pharmacology services offers into new product lines.
This financing was entirely subscribed by Arbevel Life Sciences Crossover I, a european private equity fund based in Paris (France) with a cross-over approach. TransCure bioServices will use the proceeds to expand its profitable business activities in Europe and the USA, and to develop additional platforms for international pharmaceutical and biotech companies.
Marc Le Bozec , Managing Director of Arbevel Life Sciences Crossover I Fund, will now join the Supervisory Board of the company and commented: “We are excited to collaborate with TransCure bioServices’ management in expediting its growth by addressing new markets and strengthening its commercial team”.
Patrick Nef , Chief Executive Officer and co-founder of TransCure bioServices, commented: “We welcome Arbevel as a new shareholder to boost our healthy and profitable international CRO business which generated significant growth over the past 3 years. In addition to the ongoing full human immune system mouse models for immuno-oncology, inflammation, and infectious diseases we are excited to develop new hu-liver and 100% human monoclonal antibody services. We look forward to the contribution of Marc Le Bozec in the Supervisory Committee and to benefit from his expertise of preclinical CRO business and financial markets.”
“Arbevel’s investment underlines a steppingstone for the growth of our worldwide business,” says Stéphane Legastelois , Chairman of TransCure bioServices. “It allows TransCure bioServices to widen its range of services and to investigate new exciting areas in the field of full human antibodies.”
Agile Capital Markets acted as financial advisor for TransCure bioServices in this transaction.
About TransCure bioServices SAS.
TransCure bioServices SAS is a European CRO based in France offering pre-clinical in vivo pharmacology fee-for-services to international pharmaceutical, biotech and academic customers. Uniquely designed full human immune system and hu-liver mouse models provide predictive power for drug profiling and smarter drug candidate selection for immuno-oncology, inflammation (IBD, SLE, MS, RA), auto-immune, infectious (HIV), liver diseases, and vaccines. If you are looking for check point inhibition, CART-cell designs, 100% IgG mAb, any drug profiling involving the human immune system or hu-liver, contact us at www.tcbioservices.com
About Financière Arbevel
Founded in 1997, Financière Arbevel, an entrepreneurial investment management company, has grown significantly since its takeover by the current owners in early 2009 – the AUM progressed from EUR 25m to EUR 1.6bn as of today (of which EUR 732m under the umbrella SICAV “Pluvalca” comprising 9 sub-funds). The company currently employs a total of 34 staff, of which 13 are dedicated to fund management/investment research. Financière Arbevel is recognized for its expertise within the small & mid cap asset class. We are a research-driven organization with a strong emphasis on fundamental financial and strategic analysis, close relationships with top managements of listed companies (more than 1000 company meetings last year) and a permanent quest for new investment themes offering structural growth opportunities. The digitalization, fintech, Industry 4.0, or the ageing of the world population are some of our favorite investment themes. We ensure we 3/3 are following closely the latest developments within this universe, by participating in various conferences, trade fairs, sector-specific thematic events and by meeting regularly with managements of listed companies. Our small & mid cap DNA is spread across various strategies under the PLUVALCA family of funds with a cross-asset approach comprising our core equity funds, thematic equity funds, fixed income and diversified/flexible allocation funds). In 2015, the Norwegian sovereign wealth fund chose Financière Arbevel to manage its French equity mandate. In 2018, Financière Arbevel pursued its development by launching its first European private equity fund (FPCI form or “Professional private equity investment fund”) with a cross-over approach focused on the non-listed life-science universe, with the idea of accompanying a limited number of biotechnology start-ups in their development. www.arbevel.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005005/en/
Contact:
TransCure bioServices SAS Patrick Nef, PhD Chief Executive Officer Email: info@tcbioservices.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Netmore and Cibicom Enter Strategic Partnership for Denmark and Introduce Unified Roaming Across the Nordics15.9.2026 08:00:00 CEST | Press release
Roaming with Digita provides seamless cross-border coverage while driving convergence toward a true global LoRaWAN® network Netmore Group, the leading network operator for Massive IoT, today announced that Cibicom has selected Netmore’s Operator Platform-as-a-Service (PaaS) to operate, optimize, and scale its nationwide LoRaWAN® network for Internet of Things (IoT) deployments. Cibicom is the largest LoRaWAN network operator in Denmark and provides critical communication infrastructure for nationwide broadcast and LTE450 services as well as tier 3 data center solutions and B2B fiber connectivity. The partnership means that Cibicom will replace its existing LoRaWAN Network Server with Netmore’s ThingPark Platform and that the Parties will work strategically together to ensure Danish customers can benefit from comprehensive and reliable LoRaWAN connectivity across Denmark. By leveraging Netmore's carrier-grade platform, Cibicom gains enhanced network scalability, seamless roaming, and hi
PSG Equity Holds Final Close of Third European Fund at Over €4.4 Billion15.9.2026 08:00:00 CEST | Press release
Fund hits hard cap; commitments significantly exceed size of PSG Europe IIStrong support from new and long-term investors signals continued demand for PSG Equity’s investment strategyFocused on scaling up European software and technology companies and building them into pan-European category leaders with global reach PSG Equity (“PSG”), a leading growth equity firm that specializes in partnering with software and technology-enabled services companies to drive transformational growth, today announced the final close of PSG Europe III (“PSGE III” or the “fund”) at over €4.4 billion in total committed capital. The fund reached its hard cap, receiving strong support from new and returning investors. PSGE III surpasses its €2.6 billion predecessor fund, which held its final close in October 2023. The Europe-focused fund saw commitments from state pension funds, sovereign wealth funds, insurance companies, family offices and high net worth individuals. PSGE III will continue the firm’s strat
Adabas & Natural Appoints Hans Roth as Chief Executive Officer15.9.2026 08:00:00 CEST | Press release
Experienced and accomplished enterprise technology executive to lead the next stage of AI-driven growth for the company’s mission-critical infrastructure software platform Adabas & Natural (A&N) today announced the appointment of Hans Roth as Chief Executive Officer, effective November 1. The appointment marks a defining moment as A&N enters its next chapter positioned for sustained, accelerating growth. Following the carveout of webMethods, StreamSets, Alfabet, Cumulocity, TrendMiner, and ARIS from Software GmbH, A&N is now back to its original roots as the multi-decade leading mission-critical database and infrastructure software suite. Roth joins from Red Hat, where he most recently served as Senior Vice President and General Manager for Europe, Middle East, and Africa (EMEA) and previously led Red Hat’s EMEA services business. Before joining Red Hat, Roth served as Vice President of the service delivery unit at Hewlett-Packard Enterprise for central Europe. “I’m thrilled to help bu
TreviPay Partners with Dynatos to Add e-Invoicing Capabilities to its B2B Payments Infrastructure15.9.2026 07:00:00 CEST | Press release
The partnership brings e-invoicing technology and compliance expertise into TreviPay’s B2B payments infrastructure as requirements expand across Europe and other markets TreviPay, a global B2B payments infrastructure partner, today announced a partnership with Dynatos to expand e-invoicing capabilities for TreviPay clients operating across Europe and other markets. Through the partnership, Dynatos Routty Cloud proposition will provide embedded e-invoicing technology and compliance support, helping TreviPay clients exchange invoices across different formats, networks and country requirements in Europe and other global markets. E-invoicing requirements continue to expand across Europe and other global markets, adding complexity for businesses managing invoices across more than 60 countries with mandates announced or already in place. At the same time, invoicing has become an increasingly important part of the B2B buyer experience. TreviPay research found 68% of B2B buyers are more likely
Meiji Group to Showcase Japanese-Quality CMO/CDMO Services and a Global Manufacturing Network at CPHI Milan 202615.9.2026 07:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (HQ: Chuo-ku, Tokyo; President and CEO: Toshiaki Nagasato) will debut as the Meiji Group’s Pharmaceutical Segment at CPHI Milan 2026, at Fiera Milano, Milan, Italy, October 6–8, 2026. At the exhibition, the Meiji Group’s Pharmaceuticals Segment will showcase 80 years of expertise in Japanese standard quality control, manufacturing, and supply network from Japan to Europe, India, and Southeast Asia. It will also highlight group-wide contract manufacturing, from development to supply, tailored to customer needs. Through the exhibition, Meiji Seika Pharma aims to raise global awareness of the Meiji Group’s Pharmaceutical Segment, its brands, capabilities, production capacity, and contract manufacturing services, and to forge new global partnerships to expand its CMO/CDMO business. “CPHI Milan 2026” Exhibition Overview Exhibition Name: CPHI Milan 2026 Dates: October 6 (Tue) – 8 (Thu), 2026 Venue: Fiera Milano (Milan, Italy) Exhibition Area: CMO Area Booth Numbe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom